摘要
儿童自身免疫性溶血性贫血是一种较少见的获得性自身免疫性疾病。准确的分型及病因诊断,是其诊断及治疗依据。目前儿童自身免疫性溶血性贫血主要采用经验性治疗,糖皮质激素为温抗体型一线药物。对于反复及难治患者,近年来利妥昔单抗等二线治疗在儿童中报道增加,取得一定疗效。本文就儿童自身免疫性溶血性贫血诊疗方法的选择进行总结,供临床医师参考。
Autoimmune hemolytic anemia（AIHA）is an un-common acquired immune disorder. The classification of AI-HA is based on the pattern of the direct antiglobulin test andon the immunochemical properties of the autoantibody,but also on the presence or absence of an underlying condition ordisease. Different type of AIHA has different treatment andoutcome. Treatment for AIHA has long been empirical andfirst line therapy is corticosteroids,especially for warm AIHA（w AIHA）.For relapsed or refractory AIHA,second-line thera-py,such as rituximab,may be a good alternative and has beenmore reported in childhood patients. In this article,the classi-fication and the recent progress in therapies for AIHA are discussed to provide treatment recommendations for pediatricians.
出处
《中国实用儿科杂志》
CSCD
北大核心
2014年第11期814-818,共5页
Chinese Journal of Practical Pediatrics
